A method for treating or preventing a Pneumocystis carinii infection in a mammal by administering a certain naphthoquinone compound or physiologically acceptable salts thereof.
The present invention relates to the use of 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone or a physiologically acceptable salt or other physiologically funtional derivative thereof for the manufacture of a medicament for the treatment and/or prophylaxis of toxoplasmosis in animals, to pharmaceutical compositions for the treatment and/or prophylaxis of toxoplasmosis, comprising said compound as active ingredient and to a method of treating or preventing toxoplasmosis in an animal which comprises administering to said animal an effective amount of said compound.
The invention relates to certain naphthoquinone derivatives, some of which are novel, of the general formula I ##STR1## in which R represents a hydrogen atom or a hydroxyl or an ethanoyloxy group; methods for their preparation; compositions containing such compounds and their use as pesticides, such as fungicides and, especially, insecticides and acaricides. Compounds of formula I may be derived from plants of the genus Calceolaria and the invention therefore also relates to extracts of a Calceolaria species and their use as pesticides.
The invention provides a pharmaceutical composition for the rectal administration of active principles which exhibit a prevalently topical medication action at the colon level, characterized in that said active principles are formulated in a fluid vehicle able to generate a foam on rectal administration.
The invention relates to combinations of atovaquone and proguanil, their use in the treatment and prophylaxis of parasitic infections such as protozoal parasitic infections, e.g., malaria and toxoplasmosis, and infections caused by P. carinii and their use in the manufacture of medicaments for the treatment and/or prophylaxis of such infections. The combinations can conveniently be administered in a single pharmaceutical formulation. Preferably, atovaquone and proguanil are administered in a potentiating ratio so that they act in synergy.
The present invention relates to pharmaceutical compositions for the treatment of infections caused by Microsporidia comprising treating an animal with 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone or a physiologically acceptable salt thereof.
